141 related articles for article (PubMed ID: 3122313)
1. Diminished natural killer activity in pregnancy: modulation by interleukin 2 and interferon gamma.
Vaquer S; de la Hera A; Jordá J; Martínez C; Escudero M; Alvarez-Mon M
Scand J Immunol; 1987 Dec; 26(6):691-8. PubMed ID: 3122313
[TBL] [Abstract][Full Text] [Related]
2. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy is associated with a reduction in the pattern of the cytotoxic activity displayed by lymphokine-activated killer cells.
Salméron OJ; Vaquer S; Salmerón I; Moltó L; Lapeña P; Manzano L; de las Heros JI; Alvarez-Mon M
Am J Reprod Immunol; 1991 Dec; 26(4):150-5. PubMed ID: 1840730
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
5. Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2.
Manzano L; Alvarez-Mon M; Abreu L; Antonio Vargas J; de la Morena E; Corugedo F; Duràntez A
Gut; 1992 Feb; 33(2):246-51. PubMed ID: 1541421
[TBL] [Abstract][Full Text] [Related]
6. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
Yoneda K; Yamamoto T; Ueta E; Osaki T
J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
[TBL] [Abstract][Full Text] [Related]
7. Two different maturational stages of natural killer lymphocytes in human newborn infants.
Sancho L; de la Hera A; Casas J; Vaquer S; Martínez C; Alvarez-Mon M
J Pediatr; 1991 Sep; 119(3):446-54. PubMed ID: 1715396
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
10. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
11. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
Biron CA; Young HA; Kasaian MT
J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
[TBL] [Abstract][Full Text] [Related]
13. Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.
Cordero OJ; Sarandeses CS; López JL; Nogueira M
Lymphokine Cytokine Res; 1992 Oct; 11(5):277-85. PubMed ID: 1467368
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of diminished natural killer cell activity in pregnant women and neonates.
Baley JE; Schacter BZ
J Immunol; 1985 May; 134(5):3042-8. PubMed ID: 3980989
[TBL] [Abstract][Full Text] [Related]
15. Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Trentin L; Agostini C; Chisesi T; Vespignani M; Pizzolo G; Pandolfi F; Ensoli F; Semenzato G
Leuk Res; 1989; 13(4):315-22. PubMed ID: 2497276
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
17. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
18. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
[TBL] [Abstract][Full Text] [Related]
19. Role of interleukin 2 in inducing normalization of natural killer activity in systemic lupus erythematosus.
Gaspar ML; Alvarez-Mon M; Gutiérrez C
Clin Immunol Immunopathol; 1988 Nov; 49(2):204-14. PubMed ID: 3139345
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
